8-K: Applied DNA Sciences Announces Third Quarter Fiscal Year 2024 Results, Highlights Progress in Key Business Segments

Applied DNA Sciences reported its third quarter fiscal year 2024 financial results, showcasing progress in its therapeutic DNA, molecular diagnostics, and DNA tagging segments, despite a revenue decrease due to the conclusion of a COVID-19 testing contract.

Summary

• Applied DNA Sciences announced its financial results for the third quarter of fiscal year 2024, ending June 30, 2024.
• Total revenue was approximately $798 thousand, a decrease from $2.9 million in the same period last year, primarily due to the end of a COVID-19 testing contract with CUNY.
• Gross profit was $245 thousand, compared to $1.3 million in the prior year, with a gross profit percentage of 31% versus 44%.
• Operating expenses decreased to $3.6 million from $4.1 million year-over-year, mainly due to reduced selling, general, and administrative expenses.
• The company reported a loss from operations of $3.3 million, compared to a loss of $2.9 million in the same period last year.
• Adjusted EBITDA was a negative $3.2 million, compared to a negative $2.1 million in the prior year.
• Cash and cash equivalents stood at $10.4 million, up from $7.2 million at the end of September 2023, boosted by a $10.5 million capital raise.
• The company is on track to launch a GMP facility for Linea IVT templates by the end of fiscal year 2024, with an initial annual capacity of over 5 grams.
• They have secured two GMP vendor approvals and expect GMP production runs to begin in early CY25.
• The company has established testing capacity for its TR8 PGx service, with a potential annual revenue opportunity of over $25 million.
• A multi-year commercialization agreement was signed with Indus Group for the CertainT platform, with the first purchase order expected before the end of FY24.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in the company's operational progress and future plans, the financial results show a significant decline in revenue and profitability. The company is making progress in key areas, but the financial performance is concerning.

Positives

• The company is on track to launch a GMP facility for Linea IVT templates by the end of fiscal year 2024.
• Applied DNA Sciences secured two GMP vendor approvals for Linea IVT templates.
• The TR8 PGx testing service has a potential annual revenue opportunity of over $25 million.
• A multi-year commercialization agreement was signed with Indus Group for the CertainT platform.
• The company successfully raised $10.5 million through a public offering.
• Cash and cash equivalents increased to $10.4 million.

Negatives

• Total revenue decreased to $798 thousand from $2.9 million year-over-year.
• Gross profit decreased to $245 thousand from $1.3 million year-over-year.
• The company experienced a loss from operations of $3.3 million, compared to a loss of $2.9 million in the same period last year.
• Adjusted EBITDA was a negative $3.2 million, compared to a negative $2.1 million in the prior year.

Risks

• The company has a history of net losses and limited financial resources.
• There is unknown future demand for its biotherapeutics products and services.
• The amount of revenues and profits from the Linea IVT and Linea DNA platforms is uncertain.
• There has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT platform approved for therapeutic use.
• The market acceptance for its supply chain security products and services is limited.
• The amount of revenues and profits that will result from its TR8 PGx testing service is unknown.

Future Outlook

The company anticipates revenue growth year-over-year starting in the first half of fiscal 2025, driven by key inflection points in its three business segments.

Management Comments

• James A. Hayward, Ph.D., president and CEO of Applied DNA, stated, 'FQ3 was characterized by strong execution across all three business segments.'
• He also stated, 'With a talented team and a strengthened balance sheet, we believe we are approaching key inflection points in each of our three business segments to drive total revenue growth year-over-year starting in the first half of fiscal 2025.'

Industry Context

The company's focus on PCR-based DNA technologies aligns with the growing demand for advanced therapeutics, diagnostics, and supply chain security solutions in the biotechnology industry. The development of a GMP facility for Linea IVT templates positions them to capitalize on the expanding mRNA therapeutics market. The commercialization of the TR8 PGx testing service addresses the increasing need for personalized medicine.

Comparison to Industry Standards

• Applied DNA's revenue decline due to the end of a COVID-19 testing contract is a common trend among companies that experienced a surge in testing demand during the pandemic, such as Quidel and Abbott.
• The company's focus on mRNA therapeutics development is similar to companies like Moderna and BioNTech, although Applied DNA is at an earlier stage of development.
• The establishment of a GMP facility for Linea IVT templates is a significant step, comparable to other companies investing in manufacturing capabilities for advanced therapies, such as Catalent and Lonza.
• The commercialization of the TR8 PGx testing service is in line with the industry trend towards personalized medicine, similar to companies like Myriad Genetics and Invitae.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and profitability, but encouraged by the operational progress and future plans.
• Employees may be impacted by the company's financial performance, but also motivated by the progress in key business segments.
• Customers may benefit from the company's new products and services, such as the Linea IVT templates and TR8 PGx testing service.
• Suppliers may be impacted by the company's financial performance, but also benefit from the company's growth in key business segments.
• Creditors may be concerned about the company's financial performance, but also encouraged by the company's strengthened balance sheet.

Next Steps

• The company plans to launch a GMP facility for Linea IVT templates by the end of fiscal year 2024.
• GMP production runs are expected to begin in early CY25 to supply clinical trial materials to existing customers.
• The company is targeting concierge doctor practices for the initial launch of its TR8 PGx testing service, with planned expansion to enterprise customers in early CY25.
• The company anticipates receipt of the first purchase order from Indus Group for the CertainT platform before the end of FY24.

Key Dates

Keywords

DNA technologies, PCR, Therapeutic DNA, Molecular Diagnostics, DNA Tagging, Linea IVT, Linea DNA, mRNA, GMP, TR8 PGx, CertainT, Supply Chain Security